1. Home
  2. SERV vs CSTL Comparison

SERV vs CSTL Comparison

Compare SERV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serve Robotics Inc.

SERV

Serve Robotics Inc.

HOLD

Current Price

$9.08

Market Cap

913.2M

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$24.87

Market Cap

806.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SERV
CSTL
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.2M
806.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SERV
CSTL
Price
$9.08
$24.87
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$18.60
$47.17
AVG Volume (30 Days)
3.6M
343.4K
Earning Date
03-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$908.60
$2.42
Revenue Next Year
$183.94
$12.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$4.66
$14.59
52 Week High
$18.64
$44.28

Technical Indicators

Market Signals
Indicator
SERV
CSTL
Relative Strength Index (RSI) 43.58 30.08
Support Level $8.02 $21.77
Resistance Level $11.08 $42.03
Average True Range (ATR) 0.59 0.97
MACD 0.01 0.24
Stochastic Oscillator 14.58 4.96

Price Performance

Historical Comparison
SERV
CSTL

About SERV Serve Robotics Inc.

Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: